Application of in situ potentiometric sensors to study dissolution-precipitation Application of in situ potentiometric sensors to study dissolution-precipitation Application of in situ potentiometric sensors to study dissolution-precipitation behavior of electrospray-generated loperamide nanoparticles
[email protected] of electrospray-generated loperamide nanoparticles
[email protected] of electrospray-generated loperamide nanoparticles
K. Tsinman1, O. Tsinman1, R. Lingamaneni1, J. Patel1, C.J. Batty2, D. Thao2, J.P. Wyman2 and R.A. Hoerr2K. Tsinman , O. Tsinman , R. Lingamaneni , J. Patel , C.J. Batty , D. Thao , J.P. Wyman and R.A. Hoerr1Pion Inc, 10 Cook Street, Billerica, MA 01821, USA; 2Nanocopoeia LLC, 1246 University Ave W, St. Paul, MN 55104, USAPion Inc, 10 Cook Street, Billerica, MA 01821, USA; Nanocopoeia LLC, 1246 University Ave W, St. Paul, MN 55104, USA
Flux of LPD through Double Sink™ PAMPA MembraneSupersaturation Monitoring by FDSINTRODUCTION Flux of LPD through Double Sink™ PAMPA MembraneSupersaturation Monitoring by FDSINTRODUCTION
To study LPD formulation effect on flux of the API through artificial membranes, 0.8 mL of the suspension prepared accordingto Table 1 was added to the corresponding donor chamber of µFLUX system and topped up with 19.2 mL of FaSSIF buffer.
Ability of FDS to monitor supersaturating solutions was evaluated by adding excess amount of LPD powder to buffers atdifferent pH values. Figure 7 and 8 show examples of LPD dissolution behavior at pH 8.0 and 6.5.
Compound specific potentiometric sensors can be used for real time concentration monitoring of ionizable organic compoundsoften replacing time consuming HPLC methods1. Theoretically, such free drug sensors (FDS) are supposed to detect only to Table 1 was added to the corresponding donor chamber of µFLUX system and topped up with 19.2 mL of FaSSIFblank buffer.different pH values. Figure 7 and 8 show examples of LPD dissolution behavior at pH 8.0 and 6.5.
FSD real-time detection showed that during a short supersaturation period the concentration of LPD reached 5 - 10 timesoften replacing time consuming HPLC methods1. Theoretically, such free drug sensors (FDS) are supposed to detect onlydissolved molecules since large complexes like nanoparticles cannot penetrate the sensors membrane. The purpose of this FSD real-time detection showed that during a short supersaturation period the concentration of LPD reached 5 - 10 times
higher than its equilibrium solubility even without nanoparticle formulation. The supersaturation followed by precipitation afterTable 1. Formulations used in the Flux experiment
dissolved molecules since large complexes like nanoparticles cannot penetrate the sensors membrane. The purpose of thisstudy was to determine applicability and limitations of this potentiometric technique to measure free drug concentration in the higher than its equilibrium solubility even without nanoparticle formulation. The supersaturation followed by precipitation after
about 20 min (Figure 7). This behavior was confirmed by in situ UV concentration monitoring (Figure 8).Table 1. Formulations used in the Flux experiment
study was to determine applicability and limitations of this potentiometric technique to measure free drug concentration in thepresence of nanoparticles.
Weight of
LPD in
Weight of
Excipient Volume of Load of LPD in MATERIALS AND METHODSLPD Dissolution-Precipitation, pH 8.0 LPD Dissolution-Precipitation, pH 6.5
LPD in
mixture
Excipient
in mixture Weight of
Volume of
FaSSIFblank
Load of LPD in
Suspension MATERIALS AND METHODS
25
LPD Dissolution-Precipitation, pH 8.0
1000
LPD Dissolution-Precipitation, pH 6.5 Formulationmixture
(mg)in mixture (mg)
Weight of mixture
FaSSIFblank
(mL)Suspension (mg/mL)
LPD HCl PW 25.02 N/A 25.02 2 12.51Nanoparticle powders of loperamide HCl (LPD, Figure 1)
20
25
800
900
1000 LPD HCl PW 25.02 N/A 25.02 2 12.51
LPD Kollidon Nano 25.02 25.02 50.05 2 12.51
Nanoparticle powders of loperamide HCl (LPD, Figure 1)were made using a multi-jet, multi-nozzleElectroNanospray™ system (ENS, Nanocopoeia, LLC,
Loperamide
15
20
Co
nc
µg
/mL
600
700
800
Co
nc
µg
/mL
LPD Kollidon Nano 25.02 25.02 50.05 2 12.51
LPD Soluplus Nano 25.15 25.15 50.30 2 12.58ElectroNanospray™ system (ENS, Nanocopoeia, LLC,Figure 2). Solutions of drug with either SoluPlus® or
N
Cl
10
15
Co
nc
µg
/mL
400
500
600
Co
nc
µg
/mL
LPD +Soluplus Mixture 25.30 25.34 50.64 2 12.65Figure 2). Solutions of drug with either SoluPlus® orKollidon® K17 (1% w/v each) in isopropanol:CH2Cl2 (10:90v/v) were fed at 100 µL/min/nozzle and then stored in
N
N
O
405
10
Co
nc
µg
/mL
200
300
400
Co
nc
µg
/mL
The slope of concentration-time profiles in the receivercompartment can be used to calculate the flux of LPD
v/v) were fed at 100 µL/min/nozzle and then stored insealed vials until use. Particle size of dry and water- Base: pKa 8.70; logP 3.90
N
OH
35
40LPD PWD
0
5
0
100
200compartment can be used to calculate the flux of LPDthrough artificial membrane at particular time point. As
Figure 1. Chemical structure and physico-chemical properties of LPD
sealed vials until use. Particle size of dry and water-suspended ENS powders was assessed by SEM imaging
Base: pKa 8.70; logP 3.90
Figure 2. Multi-jet nozzle with cone-jet spray plumes.
30
35
LPD-PVP Nanosusp
0
0 5 10 15 20 25 30 35 40
Time, min
0
0 10 20 30 40 50 60 70 80
Time, min
through artificial membrane at particular time point. Asevident from Figure 11, flux of LPD from
physico-chemical properties of LPD and laser diffraction, respectively (Figure 3a,b).cone-jet spray plumes.
25
30
LPD-Soluplus Nanosusp
Time, min Time, minevident from Figure 11, flux of LPD fromnanosuspension with Soluplus was the highest and itwas ~ 2 times higher than one from LPD powder. FluxFree Drug Sensors (FDS, Pion Inc., Figure 4)100 nm (D50)
20
25
LPD+Soluplus MixtureFigure 7. Concentration-time profile of LPD measured in situ by FDS: 4 mg of LPD powder was added to 20 mL of pH 8.0 buffer (a); 20 mg of LPDadded to 20 mL of FaSSIFblank buffer at pH 6.5 (b).
was ~ 2 times higher than one from LPD powder. Fluxfrom nanosuspension of LPD-Kollidon K17 and from
Free Drug Sensors (FDS, Pion Inc., Figure 4)were conditioned in the solution of LPD at the pH
100 nm (D50)
15
20added to 20 mL of FaSSIFblank buffer at pH 6.5 (b). from nanosuspension of LPD-Kollidon K17 and fromthe physical mixture of LPD with Soluplus werecomparable in value and both were higher than flux
were conditioned in the solution of LPD at the pHvalue where LPD was fully ionized. Afterconditioning sensors became specific to the drugs
10.9 μm
81.0 m
10
15comparable in value and both were higher than fluxfrom LPD powder. Flux values for the initial period (30
conditioning sensors became specific to the drugsthey had been conditioned with and could be used
81.0 μm
5
10 from LPD powder. Flux values for the initial period (30– 60 min) and closer to the end of the assay (120 –180 min) are compiled in the Table 2.
they had been conditioned with and could be usedto measure concentration of these compounds in
situ through monitoring of the change in mV0
0 50 100 150 200 250
180 min) are compiled in the Table 2.situ through monitoring of the change in mVresponse of the sensors in different
Figure 3. Particle size distribution of loperamide-SoluPlus ENS powders (a) by SEM of dry powder
0 50 100 150 200 250response of the sensors in differentconcentrations of LPD.
SoluPlus ENS powders (a) by SEM of dry powder showing diameters in fractional µm and (b) by laser diffraction 60 min after suspension in water.
Figure 11. Concentration-time profile of LPD in receiver compartment of µFLUX systemwhen introduced as 0.5 mg/mL load from different forms .
diffraction 60 min after suspension in water.
Table 2. Flux calculated from the slopes of the curves on Figure 11.when introduced as 0.5 mg/mL load from different forms .
Flux, µg/(min·cm2)
Table 2. Flux calculated from the slopes of the curves on Figure 11.
Formulation
Flux, µg/(min·cm2)
30 - 60 min 120 - 180 min
LPD PWD 1.18 0.92LPD PWD 1.18 0.92
LPD-PVP Nano 1.46 1.25
Figure 8. Concentration-time profile of LPD measured in situ by FO UV. Loads correspond to ones described on Figure 7.
LPD-PVP Nano 1.46 1.25
LPD-Soluplus Nano 2.17 2.03Figure 8. Concentration-time profile of LPD measured in situ by FO UV. Loads correspond to ones described on Figure 7.
LPD-Soluplus Nano 2.17 2.03
LPD+Soluplus Mixture 1.39 1.61LPD+Soluplus Mixture 1.39 1.61
CONCLUSIONSSolubility of LPD in the presence of Soluplus®
CONCLUSIONS
It was shown that FDS could be used in measuring in situ concentration of ionizable compounds in the presence of
Solubility of LPD in the presence of Soluplus®Figure 5. A schematic of the µFLUX apparatus showing a pair of
It was shown that FDS could be used in measuring in situ concentration of ionizable compounds in the presence of nanoparticles avoiding complicated solid separation methods. LPD nanoparticles seemed to dissolve completely in the water-based nanosuspension at concentration up to 5 mg/mL.
Figure 5. A schematic of the µFLUX apparatus showing a pair ofthe donor and receiver chambers. FO probes attached to theµDISS Profiler monitor concentrations in the donor (left) and
Figure 4. Free Drug Sensor and nanoparticles avoiding complicated solid separation methods.
This technique can be a powerful addition to in situ UV concentration monitoring in cases when particulate light scattering
LPD nanoparticles seemed to dissolve completely in the water-based nanosuspension at concentration up to 5 mg/mL.When suspension (or solution) was added to the buffer LPD was released almost immediately, with a kinetic solubility thatreached more than 80 µg/mL (at pH 8.0) before LPD began precipitating from the solution.
µDISS Profiler monitor concentrations in the donor (left) andreceiver (right) compartments. The chambers can be separated byartificial, cell-based size exclusion, or other types of membranes
Figure 4. Free Drug Sensor andReference Electrode in the solution. This technique can be a powerful addition to in situ UV concentration monitoring in cases when particulate light scattering
and additional absorption make spectroscopic measurements difficult. reached more than 80 µg/mL (at pH 8.0) before LPD began precipitating from the solution.One of the outcome of the study was the fact that in the presence of 50% wt/wt of Soluplus the solubility of LPD increased
artificial, cell-based size exclusion, or other types of membranesmounted in the Membrane Holder.
The limitation of drug selective electrode technology as any potentiometric based technique is that compound must be charged in the media of the interest.
One of the outcome of the study was the fact that in the presence of 50% wt/wt of Soluplus the solubility of LPD increasedup to 5 mg/mL in the aqueous medium regardless whether it was nanosized or not. Both techniques confirmed that LPDpowder got dissolved up to 5 mg/mL level when 5 mg/mL of Soluplus was in the background (Figures 9 and 10)
µFLUX Profiler™ fitted with µFLUX apparatus (Pion Inc., Figure 5) was used to measure simultaneously dissolutioncharacteristics (donor chamber) and concentration of LPD permeating through artificial gastro-intestinal tract mimicking charged in the media of the interest.
Nano-formulation Soluplus® provided superior solubilization for LPD that also manifested itself in the increased flux.
powder got dissolved up to 5 mg/mL level when 5 mg/mL of Soluplus was in the background (Figures 9 and 10)characteristics (donor chamber) and concentration of LPD permeating through artificial gastro-intestinal tract mimickingmembranes to the receiver chamber. Nano-formulation Soluplus® provided superior solubilization for LPD that also manifested itself in the increased flux.
Additional study should be performed to investigate interference of lipophilic and charged media or formulation components
membranes to the receiver chamber.Each pair (Figure 5) of a donor and an receiver compartment were separated by a filter-supported artificial membrane (Double-
Additional study should be performed to investigate interference of lipophilic and charged media or formulation components on the measurements.
Each pair (Figure 5) of a donor and an receiver compartment were separated by a filter-supported artificial membrane (Double-Sink™ PAMPA2) with 1.5 cm2 surface area. The donor compartment was filled with 20 mL of the media of interest while thereceiver compartment contained the same volume of Acceptor Sink Buffer at pH 7.4 (ASB-7.4, Pion Inc). The integrated fiber- on the measurements.receiver compartment contained the same volume of Acceptor Sink Buffer at pH 7.4 (ASB-7.4, Pion Inc). The integrated fiber-optic UV probes were positioned in the donor and receiver compartments allowing real time concentration monitoring in all
y = 54.211x + 303.99500
optic UV probes were positioned in the donor and receiver compartments allowing real time concentration monitoring in allchambers. Zero Intercept Method (ZIM)3 analysis was performed using Au PRO™ software version 5.1 (Pion).
REFERENCESAfter Centrifugation
y = 54.211x + 303.99
R² = 0.9992
y = 51.455x + 309.43480
RESULTS AND DISCUSSION REFERENCESAfter Centrifugationy = 51.455x + 309.43
R² = 0.9987460
mV
RESULTS AND DISCUSSION
1. Bohets H. Development of in situ ion selective sensors for dissolution. Analytica Chimica Acta 581 (2007) 181–191.440
460
mV
In Situ Concentration Measurements using Free Drug Sensors (FDS™) 1. Bohets H. Development of in situ ion selective sensors for dissolution. Analytica Chimica Acta 581 (2007) 181–191.2. A. Avdeef, O. Tsinman. PAMPA—A drug absorption in vitro model. 13. Chemical selectivity due to membrane hydrogen bonding: In combo
440
Std curve in DI+Soluplus_uncorrected
In Situ Concentration Measurements using Free Drug Sensors (FDS™)
comparisons of HDM-, DOPC-, and DS-PAMPA models. Eur. J. Pharm Sci. 2006, 28 (1), 43-59.3. K. Tsinman, O. Tsinman, B. Riebesehl, and M. Juhnke. Comparison of Naproxen Release from Nano- and Micro-Suspensions with Its
420Std curve in DI+Soluplus_uncorrected
Std curve in DI_Soluplus_corrected on 2 mg/mL stdFigure 6 shows standard curve for LPD that was used to translate mVresponse of FDS into concentration information. It has to be noted that unlike
FDS Standard Curve 3. K. Tsinman, O. Tsinman, B. Riebesehl, and M. Juhnke. Comparison of Naproxen Release from Nano- and Micro-Suspensions with Its Dissolution from Untreated and Micronized Powder. Poster presented at AAPS Annual Meeting and Exposition. October 14 -18, 2012, Chicago, IL.
400
2.3 2.8 3.3 3.8
Std curve in DI_Soluplus_corrected on 2 mg/mL std
response of FDS into concentration information. It has to be noted that unlikelinear proportionality of UV absorbance and concentration, potentiometric y = 62.763x + 299.15370
380
FD
S R
esp
on
se,
mV
FDS Standard Curve
IL.2.3 2.8 3.3 3.8logC (µg/mL)
linear proportionality of UV absorbance and concentration, potentiometricresponse is linearly proportional to the logarithm of concentration. The
y = 62.763x + 299.15
R² = 0.99
350
360
370
FD
S R
esp
on
se,
mV
Figure 9. Serial addition of LPD stock solution to the water-based mediacontaining 5 mg/mL of Soluplus. Determined concentration by UV was in
Figure 10. Standard curve collected using FDS in water-based mediacontaining 5 mg/mL of Soluplus in the background showed no evidence of
response is linearly proportional to the logarithm of concentration. Thestandard curve was then used to convert dynamic in situ millivolt response ofFDS into concentration allowing real time monitoring of LPD in the presence
330
340
350
FD
S R
esp
on
se,
mV
line with amount of LPD added.containing 5 mg/mL of Soluplus in the background showed no evidence ofLPD precipitation
FDS into concentration allowing real time monitoring of LPD in the presenceof nanoparticles. 310
320
330
FD
S R
esp
on
se,
mV
of nanoparticles. 310
0.2 0.4 0.6 0.8 1 1.2
log Conc (µg/mL)log Conc (µg/mL)
Figure 6. Standard curve (FDS mV response versuslogarithm of concentration) from adding of pre-dissolvedlogarithm of concentration) from adding of pre-dissolvedLPD into pH 8.0 buffer.
Top Related